Last update 27 Mar 2025

Margetuximab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-HER2-monoclonal-antibody-Green-Cross, Margetuximab (USAN), Margetuximab-cmkb
+ [3]
Target
Action
antagonists
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (16 Dec 2020),
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10446Margetuximab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HER2 Positive Breast Cancer
United States
16 Dec 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastrooesophageal junction cancerPhase 3
United States
30 Sep 2019
Gastrooesophageal junction cancerPhase 3
China
30 Sep 2019
Gastrooesophageal junction cancerPhase 3
Germany
30 Sep 2019
Gastrooesophageal junction cancerPhase 3
Italy
30 Sep 2019
Gastrooesophageal junction cancerPhase 3
Poland
30 Sep 2019
Gastrooesophageal junction cancerPhase 3
Singapore
30 Sep 2019
Gastrooesophageal junction cancerPhase 3
South Korea
30 Sep 2019
Gastrooesophageal junction cancerPhase 3
Taiwan Province
30 Sep 2019
Gastrooesophageal junction cancerPhase 3
United Kingdom
30 Sep 2019
HER2-positive gastric cancerPhase 3
United States
30 Sep 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
86
iigdykomgl(eydlwhoxgx) = yuubaeixwe ajtceckqqk (dkfviamkvm )
-
25 Apr 2023
Phase 3
624
Physician's choice of chemotherapy.+Margetuximab
(Margetuximab Plus Chemotherapy)
ilmzrcwzxx(rsitwiklrk) = lorexsnnti lfbvnilbgn (zyrquwyrlr, voznylnzjz - nvecopopqn)
-
23 Nov 2022
Physician's choice of chemotherapy.+Trastuzumab
(Trastuzumab Plus Chemotherapy)
ilmzrcwzxx(rsitwiklrk) = lnpvgxnchr lfbvnilbgn (zyrquwyrlr, qkbikmaodm - piudcgbqdf)
Phase 3
-
Chemotherapy+Margetuximab
dnathgdghj(faelxsfxxq) = banlwfritq fanfnkkupi (oyzffqspbn )
Superior
09 Nov 2022
Chemotherapy+Trastuzumab
dnathgdghj(faelxsfxxq) = ierduvyggx fanfnkkupi (oyzffqspbn )
Phase 3
536
Chemotherapy+Margetuximab
kxeuscydel(dmfqkxqeol) = qjgtukchdi runxmktock (oiqhzklofu, 18.89 - 25.07)
Non-superior
04 Nov 2022
Chemotherapy+Trastuzumab
kxeuscydel(dmfqkxqeol) = bsozxndqia runxmktock (oiqhzklofu, 18.69 - 24.18)
Phase 2/3
HER2 Positive Gastroesophageal Adenocarcinoma
First line
HER2 Positive | PD-L1 Positive
43
hblaazftjp(kvomielchx) = rlfduztouz nokmkcipif (cwhfzcorsp )
Positive
24 Aug 2022
Phase 1/2
95
(Margetuximab (10 mg/kg) Plus Pembrolizumab (200 mg))
abyyxwydvf = samgziomsu zfzokammle (tondynfahl, fsxuguggbs - hioiltuamg)
-
04 Aug 2022
(Margetuximab (15 mg/kg) Plus Pembrolizumab (200 mg))
abyyxwydvf = scgntrfcoq zfzokammle (tondynfahl, ynydawrewo - saekujdvll)
Phase 2/3
Metastatic HER2 positive gastroesophageal junction cancer
First line
HER2+ | PD-L1+ | microsatellite instability
-
ydfyckxvpu(nlcftvqien) = zrprgruxno srbswzztwi (kvubijmqqz )
Positive
03 Jul 2021
Phase 3
536
Margetuximab 15 mg/kg Q3W
twedmhpqja(ulecslmziz) = 9.6% had > 15% reduction in LVEF with a median time to > 15% reduction of 49 days ybuiwgswzo (ybudsgpmyz )
Positive
15 Feb 2021
Other doses of Margetuximab (0.1 - 18 mg/kg)
Phase 3
536
Margetuximab + Chemotherapy
kkpzitafbe(dylkogqaxv) = A higher proportion of patients experienced IRRs on the M arm (35 [13.3%]) than on the T arm (9 [3.4%]). Most IRRs in both groups were severity Grade 1 or 2, occurred on Cycle 1 Day 1, and resolved within 24 hours. In patients receiving M, Grade 3 IRR occurred in 4 patients (1.5%), including 3 after vinorelbine and 1 after eribulin. Adverse events associated with Grade 3 IRRs included chills, fever, nausea, diarrhea, dyspnea, and/or hypertension. Two patients receiving M (0.8%) discontinued due to IRR, versus none on T. Of patients with IRRs, the most common symptoms in both treatment groups were chills (M: 17 [48.6%]; T: 5 [55.6%]) and fever (M: 13 [37.1%]; T: 2 [22.2%]). There was no observed hypotension in either group. In both groups, more than half of IRR events were addressed by dose interruption only. All IRRs all were medically manageable. IRR rates were higher in patients without premedication for both groups. Of 264 subjects receiving M, 218 (82.6%) received premedication and 46 (17.4%) did not; IRRs were observed in 28 (12.8%) of those receiving premedication and 7 (15.2%) of those not premedicated. All 4 patients on M with Grade 3 IRRs received premedication, 3 with steroids. Of 266 subjects receiving T, 173 (65%) received premedication and 93 (35%) did not; IRRs were observed in 5 (2.9%) of those receiving premedication and 4 (4.3%) of those not premedicated. IRR risk was unaffected by chemotherapy subgroup or CD16A genotype. nnopqupchs (vtjjspmlhw )
Positive
15 Feb 2021
Trastuzumab + Chemotherapy
Phase 3
536
gppsxxypif(uopvtvggfx) = xdodqhhygb yqgogbjqev (aieodqvdhz )
Positive
22 Jan 2021
gppsxxypif(uopvtvggfx) = dugvuizagd yqgogbjqev (aieodqvdhz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free